Selank

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in cooperation with the V.V. Zakusov Scientific Research Institute of Pharmacology. The peptide is a metabolically stable analog of tuftsin, a naturally occurring tetrapeptide (Thr- Lys-Pro-Arg) found in the heavy chain of human immunoglobulin G, which plays a role in innate immune regulation. The addition of a Pro-Gly-Pro tripeptide to the C-terminus of tuftsin confers greater metabolic stability and an extended duration of action, allowing Selank to cross the blood-brain barrier and interact with central nervous system targets. Selank was developed as an alternative to benzodiazepine medications for the treatment of anxiety. Unlike traditional anxiolytics that directly activate GABA receptors, Selank functions as a positive allosteric modulator of the GABAergic system. This distinction is critical because it means Selank enhances the natural activity of GABA without the sedation, cognitive impairment, physical dependence, or withdrawal symptoms associated with benzodiazepines such as diazepam, phenazepam, and alprazolam. The peptide has been approved as a prescription medication in Russia since the early 2000s for the treatment of generalized anxiety disorder (GAD), neurasthenia (chronic fatigue accompanied by anxiety), and stress-related conditions. In the United States, Selank remains a research compound without FDA approval and is not classified as a controlled substance. What makes Selank particularly noteworthy is its multi-pathway mechanism of action. It simultaneously modulates GABA neurotransmission, influences serotonin and dopamine metabolism, increases brain-derived neurotrophic factor (BDNF) expression, regulates enkephalin activity, and retains immunomodulatory properties from its parent molecule tuftsin. This gives Selank a unique pharmacological profile that is simultaneously anxiolytic, nootropic, and immunomodulatory. For individuals dealing with chronic stress, anxiety, or cognitive fatigue, Selank offers a fundamentally different approach than stimulants or traditional pharmaceuticals. It calms without sedating and sharpens focus without causing jitteriness or dependence.

How It Works

GABAergic System Modulation

The primary mechanism underlying Selank’s anxiolytic effects involves the GABAergic system. Gamma-aminobutyric acid (GABA) is the brain’s principal inhibitory neurotransmitter. When GABA binds to its type A receptors (GABAA), it increases chloride ion conductance, hyperpolarizes the postsynaptic neuron, and reduces neuronal excitability. This is the same system targeted by benzodiazepines, barbiturates, and alcohol.

Selank acts as a positive allosteric modulator of GABAA receptors. Rather than binding directly to the GABA binding site (as benzodiazepines do at the benzodiazepine binding site), Selank appears to bind at a related but distinct allosteric site on the receptor complex. This binding changes the receptor’s conformation in a way that increases the affinity of GABA for its own binding site, thereby enhancing inhibitory neurotransmission. The result is anxiolysis without the direct receptor activation that produces sedation, amnesia, and dependence. Research by Kasian et al. (2019) using radioligand binding studies confirmed that Selank can compete with diazepam for binding sites on the GABAA receptor complex but produces functionally different downstream effects, supporting the hypothesis of a distinct allosteric binding site. Gene expression studies by Filatova et al. (2017) demonstrated that Selank administration altered the expression of 45 genes involved in GABAergic neurotransmission within one hour, and these changes were positively correlated with those produced by GABA itself.

BDNF Upregulation

Selank increases the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex. BDNF is a neurotrophin that supports the survival and growth of neurons, promotes synaptic plasticity, and is essential for memory formation and learning. Research by Inozemtseva et al. (2008) demonstrated that intranasal Selank administration regulated BDNF expression in the rat hippocampus, providing a mechanistic basis for the peptide’s observed cognitive-enhancing effects. The upregulation of BDNF also contributes to Selank’s potential neuroprotective properties, as BDNF signaling through the TrkB receptor pathway is critical for neuronal resilience under stress conditions.

Serotonin and Dopamine Modulation

Selank influences serotonergic neurotransmission by modulating serotonin metabolism and receptor expression. Research conducted in murine models has demonstrated that Selank can regulate serotonin receptor levels in the brain, potentially enhancing the effects of this mood- regulating neurotransmitter. This serotonergic activity contributes to Selank’s mood-stabilizing effects and may explain its potential utility as an adjunctive treatment in anxious depression. The peptide also affects dopaminergic and noradrenergic systems, supporting focus, motivation, and cognitive drive. Unlike stimulant medications, these effects occur without overstimulation, contributing to the “calm focus” that users commonly report.

Enkephalin Regulation

Selank inhibits the enzymatic degradation of enkephalins, which are endogenous opioid peptides involved in mood regulation and the natural stress response. Clinical research by Zozulia et al. (2008) found that patients with generalized anxiety disorder had decreased enkephalin levels, and Selank treatment increased these levels while simultaneously improving anxiety symptoms. This enkephalinergic activity provides an additional pathway through which Selank exerts its anxiolytic effects, independent of its GABAergic modulation.

Immunomodulatory Properties

As a structural analog of tuftsin, Selank retains immunomodulatory properties from its parent molecule. Research has demonstrated that Selank can influence cytokine expression and modulate immune cell activity, including effects on lymphocytes and leukocytes. The peptide has shown potential antiviral properties in experimental models of influenza infection (Ershov et al., 2009). These immunomodulatory effects are particularly relevant for individuals experiencing chronic stress, which typically suppresses immune function through sustained activation of the hypothalamic-pituitary-adrenal (HPA) axis.

Benefits

Anxiety Reduction Without Sedation

The primary benefit of Selank is clinically meaningful anxiety relief without compromising cognitive function or alertness. In comparative clinical trials, Selank produced anxiolytic effects equivalent to benzodiazepines (both medazepam and phenazepam) as measured by the Hamilton Anxiety Rating Scale (HAM-A) and the Zung Self-Rating Anxiety Scale. Unlike the benzodiazepine comparators, Selank did not cause sedation, drowsiness, or cognitive dulling. This makes it suitable for daytime use during work, study, or any activity requiring full cognitive engagement.

Cognitive Enhancement

Selank functions as a nootropic, improving memory, attention, and information processing. Animal studies have demonstrated enhanced learning and memory formation with Selank administration. Human users consistently report improved focus, particularly under stressful conditions. The underlying mechanism involves BDNF upregulation in the hippocampus and cortex, which supports synaptic plasticity—the neurobiological foundation of learning and memory. Notably, most anxiolytic medications impair cognition as a side effect; Selank does the opposite by simultaneously reducing anxiety and enhancing cognitive performance.

Stress Resilience

By modulating the hypothalamic-pituitary-adrenal (HPA) axis, Selank helps regulate the body’s stress response at a fundamental level. With continued use, individuals report feeling more resilient to daily stressors rather than simply having their anxiety symptoms suppressed. This distinction is important because it suggests Selank helps restore physiological balance in the stress response system rather than merely masking symptoms. The anxiolytic effects have been shown to persist for up to one week after discontinuing the peptide, further supporting a restorative rather than suppressive mechanism.

No Dependence or Withdrawal

Unlike benzodiazepines, Selank does not cause physical dependence, tolerance requiring dose escalation, or withdrawal symptoms upon discontinuation. Clinical studies have specifically

confirmed the absence of these adverse effects. This safety profile allows Selank to be used as needed or in cycles without the risk of becoming dependent on it to function normally.

Immune Support

Selank retains immunomodulatory properties from its parent molecule tuftsin. Research has demonstrated effects on cytokine expression and potential antiviral activity. While this is considered a secondary benefit, it is clinically relevant for individuals dealing with chronic stress, which typically suppresses immune function through sustained cortisol elevation and HPA axis dysregulation.

What the Science Shows

Selank has accumulated more human clinical data than most research peptides, primarily from Russian clinical studies conducted under rigorous protocols.

Zozulia et al. (2008), Zhurnal Nevrologii i Psikhiatrii This study compared Selank to medazepam (a benzodiazepine) in 62 patients diagnosed with generalized anxiety disorder and neurasthenia. Both treatment groups showed similar reductions in anxiety as measured by the Hamilton Anxiety Rating Scale and the Zung Self-Rating Anxiety Scale. However, Selank also produced anti-asthenic (energy-boosting) and psychostimulant effects that the benzodiazepine comparator did not. The researchers found that patients with GAD had decreased blood levels of enkephalins, and Selank treatment increased these levels while improving clinical symptoms. This study provided the first evidence that Selank’s anxiolytic mechanism may involve enkephalin modulation in addition to its GABAergic effects.

Seredenin et al. (2014), Zhurnal Nevrologii i Psikhiatrii A comparative study evaluating Selank versus phenazepam in 60 patients with anxiety disorders. Selank produced pronounced anxiolytic effects with mild nootropic benefits. A notable finding was that the anxiolytic effect persisted for one week after the last dose of the peptide, suggesting a restorative rather than suppressive mechanism. Selank also improved quality-of-life scores without the cognitive side effects associated with phenazepam use. The researchers concluded that Selank represented a viable alternative to benzodiazepines with a superior tolerability profile.

Filatova et al. (2017), Frontiers in Pharmacology This molecular study examined how Selank affects gene expression related to GABAergic neurotransmission in neuroblastoma IMR-32 cells. Researchers found that Selank administration significantly altered the expression of 45 genes involved in neurotransmission within one hour. The changes were positively correlated with those produced by GABA itself, supporting the hypothesis that Selank works through GABAergic mechanisms. However, the gene expression profiles were not identical, suggesting that Selank acts allosterically rather than through the primary GABA binding site.

Kasian et al. (2019), Current Protein and Peptide Science

Radioligand binding studies demonstrated that Selank acts as a positive allosteric modulator of GABAA receptors. The research showed that Selank can compete with diazepam for binding sites on the receptor complex but produces functionally different effects, confirming that it binds to a related but distinct site. This study provided direct biochemical evidence for the mechanism underlying Selank’s ability to produce benzodiazepine-like anxiolysis without benzodiazepine- like side effects.

Volkova et al. (2016), Frontiers in Pharmacology This in vivo study analyzed the expression of 84 genes involved in neurotransmission in the frontal cortex of rats following Selank or GABA administration. Significant changes were found in 45 genes one hour after administration of either compound, with a strong positive correlation between the two expression profiles. Three hours after administration, 22 genes showed altered expression. The study confirmed that Selank’s molecular mechanism is associated with allosteric modulation of the GABAergic system and demonstrated the peptide’s complex effects on nerve cell gene expression.

Ershov et al. (2009), Voprosy Virusologii

This study investigated the antiviral activity of Selank in an experimental influenza infection model. The results demonstrated that Selank exhibited immunomodulatory and antiviral properties, supporting the peptide’s dual role as both a neurotropic and immunomodulatory compound. The antiviral effects were attributed to Selank’s influence on cytokine expression and immune cell activation.

Inozemtseva et al. (2008), Doklady Biological Sciences

This study demonstrated that intranasal administration of Selank regulated BDNF expression in the rat hippocampus in vivo. The findings provided a mechanistic basis for the cognitive- enhancing effects observed with Selank use and established a connection between the peptide’s nootropic properties and neurotrophin signaling pathways.

Dosing Protocol

Selank can be administered either intranasally or subcutaneously. In Russian clinical practice, intranasal administration is the standard route. In research settings, subcutaneous injection is commonly preferred for more consistent and predictable dosing.

Understanding the Routes

Intranasal administration allows rapid absorption with some degree of direct delivery to the central nervous system, bypassing the blood-brain barrier. This is the traditional route used in Russian clinical protocols and provides the fastest onset of effects. Subcutaneous injection provides systemic delivery with predictable absorption kinetics and consistent dosing. Both routes are effective, and the choice is typically based on personal preference and convenience.

Anxiolytic and Nootropic Protocol

For general anxiety reduction and cognitive support:

• Dose: 300 to 500 mcg daily
• Frequency: Once daily
• Route: Subcutaneous or intranasal
• Timing: Morning or early afternoon
• Cycle: 10 to 14 days on, followed by 7 to 14 days off
• Rationale: This protocol aligns with Russian clinical protocols and provides anxiolytic

and nootropic benefits without building tolerance

Acute Stress or Demanding Periods

For short-term use during high-stress situations:

• Dose: 200 to 400 mcg
• Frequency: Once or twice daily as needed
• Duration: Use during the stressful period, then discontinue
• Rationale: Selank produces effects within hours to days and does not require a loading

phase

Stacking With Semax

Selank and Semax are commonly used together in complementary fashion. Selank provides the calming, anxiolytic baseline while Semax delivers stimulating, focus-enhancing effects. The combination produces calm focus without sedation or jitteriness.

• Selank: 200 to 300 mcg in the morning
• Semax: 200 to 400 mcg in the morning or early afternoon
• Rationale: The compounds work through different mechanisms and complement each

other without interaction concerns

Why Cycling Matters

While Selank does not cause dependence, cycling is recommended to maintain receptor sensitivity and allow assessment of baseline status. The anxiolytic effects often persist after discontinuation, so continuous daily use is not necessary for sustained benefit. A typical cycle of 10 to 14 days on followed by 7 to 14 days off provides optimal results.

Draw Volumes by Vial Size

Zesty Rat Research offers Selank in 10 mg vials.

10 mg Vial (2 mL Reconstitution = 5 mg/mL)

Dose Volume Units on Syringe Vial Duration 200 mcg 0.04 mL 4 units 50 days 300 mcg 0.06 mL 6 units 33 days 400 mcg 0.08 mL 8 units 25 days 500 mcg 0.10 mL 10 units 20 days

10 mg Vial (3 mL Reconstitution = 3.33 mg/mL)

Dose Volume Units on Syringe Vial Duration 200 mcg 0.06 mL 6 units 50 days 300 mcg 0.09 mL 9 units 33 days 400 mcg 0.12 mL 12 units 25 days 500 mcg 0.15 mL 15 units 20 days The 3 mL reconstitution provides slightly easier measurements for lower doses.

Reconstitution Instructions

1. Remove the flip-off cap from the vial and wipe the rubber stopper with an alcohol swab. 2. Draw your chosen volume of bacteriostatic water into a sterile syringe (2 mL or 3 mL). 3. Insert the needle through the rubber stopper at an angle. 4. Inject the water slowly down the inside wall of the vial to avoid foaming. 5. Gently swirl or roll the vial until the powder is fully dissolved. Do not shake vigorously. 6. The solution should be clear and colorless. Discard if cloudy or containing particles. 7. Label the vial with the reconstitution date and concentration. 8. Store in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius). 9. Use within 30 days for optimal potency.

Side Effects

Common Effects

• Mild nasal irritation (with intranasal administration)
• Transient headache (occasional, typically resolves without intervention)
• Mild fatigue in some users (uncommon)

What Selank Does Not Cause

• Sedation or drowsiness
• Cognitive impairment or memory problems
• Physical dependence or withdrawal symptoms
• Tolerance requiring dose increases

Clinical Trial Safety Data

In comparative studies with benzodiazepines, Selank demonstrated no significant adverse effects. Researchers specifically noted the absence of sedation, addiction potential, and cognitive side effects that are common with traditional anxiolytic medications. The peptide’s safety profile was consistently superior to the benzodiazepine comparators across all clinical endpoints.

Considerations

• Effects on pregnancy and breastfeeding are unknown; avoid use in these populations.
• Long-term safety data beyond clinical trial periods is limited.
• Individual responses vary; some people respond better to intranasal versus subcutaneous

administration.

Contraindications and Precautions

Avoid If

• Pregnant or breastfeeding (not studied; unknown risks to the fetus or infant)
• Currently taking benzodiazepines or other GABAergic medications (potential additive

interaction)

• History of allergic reactions to peptides

Use With Caution If

• Taking medications that affect serotonin (SSRIs, SNRIs), as Selank also modulates

serotonergic neurotransmission

• History of autoimmune conditions (due to Selank’s immunomodulatory effects)
• Currently using other nootropics or cognitive enhancers (start with lower doses to assess

combined effects)

Not a Replacement For

• Professional mental health treatment for severe anxiety or depression
• Proper sleep, nutrition, and stress management practices
• Medical evaluation of underlying conditions causing anxiety

Comparison to Similar Compounds

Compound Primary Effect Mechanism Sedation Dependence Selank Anxiolytic / GABA allosteric None None Nootropic modulation Semax Nootropic / BDNF / Dopamine None None

Focus

Diazepam Anxiolytic Direct GABA Yes High agonist Phenibut Anxiolytic GABA-B agonist Yes Moderate L-Theanine Calming Glutamate / GABA Mild None

Selank occupies a unique position among anxiolytic and nootropic compounds. It provides benzodiazepine-level anxiety relief through a fundamentally different mechanism that avoids the downsides of direct GABA receptor activation, including sedation, tolerance, and dependence. Semax is its natural complement for cognitive enhancement without the calming effect, and the two peptides are frequently stacked together in research and clinical practice.

Success Tips

Start Low

Begin with 200 to 300 mcg daily to assess your individual response. Some people are sensitive to GABAergic compounds and may notice effects at lower doses. Increase to 400 to 500 mcg if needed after several days of assessment.

Morning Dosing

Administer Selank in the morning or early afternoon. While it does not cause sedation for most people, some individuals notice a relaxing effect that could interfere with tasks requiring high alertness if taken later in the day.

Combine With Lifestyle Practices

Selank works best as part of a broader stress management approach. The peptide helps regulate your stress response at a neurochemical level, but addressing the sources of stress in your life remains essential. Pair Selank use with sleep optimization, regular exercise, and mindfulness practices for the best results.

Consider the Semax Stack

If you require both anxiety reduction and cognitive enhancement, the Selank plus Semax combination is well-established in both clinical and research settings. Selank provides the calm baseline while Semax sharpens focus and attention. The two peptides work through different mechanisms and complement each other effectively.

Track Your Response

Keep a log of your anxiety levels, focus, mood, and overall cognitive performance. The effects of Selank can be subtle at first but build progressively over the course of a cycle. Tracking helps you identify the optimal dose, timing, and cycle length for your individual needs.

Storage and Handling

Before Reconstitution

• Store lyophilized (powder) vials in the freezer at minus 4 degrees Fahrenheit (minus 20

degrees Celsius) for long-term storage.

• Can also be stored in the refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees

Celsius) for shorter periods.

• Protect from light and moisture.
• Do not use past the expiration date.

After Reconstitution

• Refrigerate at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius).
• Use within 30 days for optimal potency.
• Do not freeze after reconstitution.
• Keep the rubber stopper clean between uses by wiping with an alcohol swab.
• If the solution becomes cloudy or contains visible particles, discard the vial and use a

new one.

Legal Status

Russia and CIS Countries: Approved prescription medication for the treatment of anxiety disorders and neurasthenia.

United States: Not FDA approved. Available as a research compound. Not scheduled as a controlled substance under the Controlled Substances Act. WADA Status: Not currently listed on the World Anti-Doping Agency prohibited list. Athletes should verify current regulations with their governing body before use. Regulatory Note: Selank has decades of clinical use in Russia and has completed Stage III clinical trials for anxiety-related conditions. The absence of FDA approval reflects the fact that the regulatory pathway has not been pursued in the United States market, not a determination of safety or efficacy concerns.

Frequently Asked Questions

How quickly does Selank work? Most individuals notice effects within one to three days. The anxiolytic effect builds progressively over the first week of use. Unlike benzodiazepines, which produce effects within 30 minutes through direct receptor activation, Selank produces a more gradual, sustained effect through its allosteric modulation of the GABAergic system.

Can I use Selank daily?

Yes, but cycling is recommended. A typical protocol is 10 to 14 days on followed by 7 to 14 days off. The anxiolytic effects often persist during the off period, and cycling helps maintain receptor sensitivity over time.

Is Selank better than Semax?

They serve different primary purposes and are not directly interchangeable. Selank is primarily anxiolytic with secondary cognitive benefits. Semax is primarily nootropic with secondary mood-stabilizing benefits. Many people use both together for complementary effects, with Selank providing the calm baseline and Semax enhancing focus and attention.

Will Selank make me tired? No. Unlike benzodiazepines, Selank does not cause sedation or drowsiness. Some users report a sense of calm that could be perceived as relaxation, but it does not impair alertness, reaction time, or cognitive function.

Can I take Selank with other medications?

Exercise caution when combining Selank with other GABAergic compounds (benzodiazepines, phenibut, alcohol) as effects may be additive. Consult a healthcare provider if you are taking prescription medications for anxiety, depression, or any condition affecting the central nervous system.

Nasal spray or injection? Both routes of administration are effective. Intranasal delivery is more convenient and provides rapid absorption with some degree of direct central nervous system delivery. Subcutaneous injection provides more consistent and predictable dosing. The choice is typically based on personal preference and practical convenience.

References

1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. 2. Seredenin SB, Kozlovskaia MM, et al. A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. 3. Filatova E, Kasian A, Kolomin T, et al. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Frontiers in Pharmacology. 2017;8:89. 4. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behavioural Neurology. 2017. 5. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. 6. Ershov FI, et al. Antiviral activity of immunomodulator Selank in experimental influenza infection. Vopr Virusol. 2009;54(5):19-24. 7. Inozemtseva LS, Karpenko EA, Dolotov OV, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. 8. Kasian A, Kolomin T, Andreeva L, et al. Modulation of GABAA Receptor by Selank. Current Protein and Peptide Science. 2019;20(12):1189-1193.